Tumor-propagating glioblastoma (GBM) stem-like cells (GSCs) of the proneural and mesenchymal molecular subtypes have been described. However, it is unknown if these two GSC populations are sufficient to generate the spectrum of cellular heterogeneity observed in GBM. The lineage relationships and niche interactions of GSCs have not been fully elucidated. We perform single-cell RNA-sequencing (scRNA-seq) and matched exome sequencing of human GBMs (12 patients; >37,000 cells) to identify recurrent hierarchies of GSCs and their progeny. We map sequenced cells to tumor-anatomical structures and identify microenvironment interactions using reference atlases and quantitative immunohistochemistry. We find that all GSCs can be described by a single axis of variation, ranging from proneural to mesenchymal. Increasing mesenchymal GSC (mGSC) content, but not proneural GSC (pGSC) content, correlates with significantly inferior survival. All clonal expressed mutations are found in the GSC populations, with a greater representation of mutations found in mGSCs. While pGSCs upregulate markers of cell-cycle progression, mGSCs are largely quiescent and overexpress cytokines mediating the chemotaxis of myeloid-derived suppressor cells. We find mGSCs enriched in hypoxic regions while pGSCs are enriched in the tumor's invasive edge. We show that varying proportions of mGSCs, pGSCs, their progeny and stromal/immune cells are sufficient to explain the genetic and phenotypic heterogeneity observed in GBM. This study sheds light on a long-standing debate regarding the lineage relationships between GSCs and other glioma cell types.
Introduction
Glioblastoma (GBM) is the most aggressive cancer of the adult brain. GBM genetics have been studied extensively and yet targeted therapeutics have produced limited results. GBM remains essentially incurable.
GBMs have been classified into subtypes that have prognostic value based on gene expression (1). We and others have shown that GBMs contain heterogeneous mixtures of cells from distinct transcriptomic subtypes (2, 3) . This intratumor heterogeneity is at least partially to blame for the failures of targeted therapies.
GBM-propagating stem-like cells (GSC) have been identified that express genes matching the mesenchymal (e.g. CHI3L1(YKL-40), CD44) and proneural (e.g. OLIG2, DLL3) transcriptomic subtypes (e.g. 4). However, the lineage relationship between proneural GSCs (pGSC) and mesenchymal GSCs (mGSCs) is unknown. Surprisingly little is known about the cellular progeny of GSCs in vivo and their interactions with their microenvironment. It is unclear if proneural and/or mesenchymal GSCs are sufficient to generate the heterogeneity observed in GBM.
We performed single-cell RNA sequencing (scRNA-seq) and wholeexome DNA sequencing (exome-seq) of specimens from untreated human GBMs. We integrated this with meta-analysis of sequencing data from
The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) and anatomical data from The Glioblastoma Atlas Project (GAP) (http://glioblastoma.alleninstitute.org/). Using immunohistochemistry (IHC) and automated image analysis of human GBM microarrays we validated phenotypes at the protein level.
We show that all GBM cells can be described by a single axis of gene signature, which ranges from proneural to mesenchymal. At the extremes of this axis reside stem-like cells which express canonical markers of mGSCs and pGSCs. All clonal expressed mutations in our specimens are found in the GSC subpopulations, with mGSCs having a higher representation of mutations. Our analysis shows that mGSCs, pGSCs, their progeny and stromal/immune cells are sufficient to explain the heterogeneity observed in GBM.
Results

Single-cell mRNA and bulk DNA profiling of human GBMs
We applied scRNA-seq to biopsies from 8 primary untreated human GBMs (table S1). Our goal was to profile both for cellular coverage (to survey cellular phenotypes) and for transcript coverage (to compare genetics). Therefore, we performed scRNA-seq on 6/8 samples via the 10X Genomics Chromium platform (10X) to obtain 3' sequencing data for 37,196 cells. ScRNA-seq of the other 2/8 cases was done using the Fluidigm C1 platform (C1), which yielded full-transcript coverage for 192 cells. We incorporated 4 more published cases from our C1 pipeline, adding 384 cells (3) . For 4 of the 10X cases and 4 of the C1 cases, the biopsies were minced, split and both scRNA-seq and exome sequencing (exome-seq) were performed (table S1). In total, scRNA-seq of 37,772 cells from 12 cases were used in this study. We applied our pipeline for scRNA-seq quality control (5), quantification of expressed mutations (3, 6) , and cell-type identification (7, 8) . This identified 6,295 tumor-infiltrating stromal and immune cells based on expressed mutations, clustering and canonical marker genes ( Fig. 1 A-B and Fig. S1A -D). We term the remaining 26,215 cells neoplastic, as they express clonal malignant mutations that have been validated by exome-seq (table S2). Only neoplastic cells were used for all subsequent analyses.
The transcriptional phenotypes of GBM neoplastic cells can be explained by a single axis that varies from proneural to mesenchymal
An unbiased principal component analysis (PCA) revealed two patientindependent clusters of neoplastic cells (Fig. 1C , S1E-F; table S3). A differential-expression test between clusters identified canonical markers of the proneural (e.g. PDGFRA) and mesenchymal (e.g. CD44) subtypes as significant (table S4) . Mesenchymal cells significantly over-express markers of response to hypoxia (e.g. HIF1A) and cytokines that promote myeloid-cell chemotaxis (e.g. CSF1, CCL2, CXCL2). However, mesenchymal cells do not express high levels of MKI67 or other markers of cell-cycle progression. Conversely, proneural cells express high levels of MKI67 as well as cyclindependent kinase (Fig. 1D ). We estimated the fraction of actively cycling cells using the Seurat package (9) . By this metric, 15.6% of proneural cells are cycling compared to 2.9% of mesenchymal cells (Fig. 1E ). Importantly, all our clinical specimens (assessed via either 10X or C1) contain cells of both phenotypes: proliferating proneural cells and mesenchymal cells with a quiescent, cytokine-secretory phenotype.
Cells at the left and right extremes of principal component 1 (PC1) express high levels pGSC or mGSC markers (4) respectively, as indicated by PC1 gene loadings (Fig. 1F , S1D-E). We therefore interpreted the top-loading genes from each direction as representing pGSC and mGSC gene signatures. We used those signatures to score all cells for stemness, controlling for technical variation as previously described (9, 10) . Principal component 2 (PC2) correlates with cycling cells (Fig. 1G) . Thus, while stemness correlates with cell cycle for both proneural and mesenchymal cells, more pGSCs than mGSCs express markers of cell-cycle progression, and at higher levels.
GBM cells are stratified by differentiation gradients observed in gliogenesis
In our differential expression test we observed that proneural cells specifically express markers of the oligodendrocyte lineage (e.g. OLIG2, SOX10), while mesenchymal cells instead express markers of astrocytes (e.g. GFAP, AQP4). We evaluated the mGSC and pGSC gene signatures in scRNA-seq of glia from fetal and adult human brain (11, 12) . We found that pGSC-signature genes are enriched in oligodendrocyte progenitor cells. The mGSC signature, however, is comprised of genes expressed by neural stem cells as well as markers of astrocytes ( Fig. 2A and 2B ).
In addition to mGSCs and pGSCs, we find neoplastic cells (possessing clonal malignant mutations) that do not express stemness or cell-cycle signatures above background. Instead they express either markers of differentiated astrocytes (e.g. ALDOC) or differentiated oligodendrocytes (e.g. MAG, MOG). While the GSCs express high levels of positive WNT-pathway regulators, these more differentiated cells express high levels of WNT-pathway agonists (Fig. S2A ). Thus, GBMs contain mesenchymal and proneural populations that align with astrocyte and oligodendrocyte differentiation gradients respectively.
PGSCs, mGSCs, their differentiated progeny and stromal/immune cells explain the phenotypic heterogeneity observed in GBM
We found that our mGSC and pGSC gene signatures are co-expressed across TCGA datasets (Fig. 2C) . While mGSC and pGSC signature genes are correlated among themselves, the mGSC and pGSC signatures are anti-correlated with each other. Moreover, the signature for cell-cycle progression obtained from PC2 more strongly correlates in TCGA data with the pGSC signature than the mGSC signature, consistent with our scRNA-seq data.
Using our scRNA-seq data and published scRNA-seq from human brain tissue (11, 12) as a basis, we pooled reads across cells of the same type. This yielded data-driven profiles for mGSCs, pGSCs, astrocytes, oligodendrocytes, neurons, endothelial cells, myeloid cells and T-cells. We then used these cell-type signatures as predictors in a linear regression model. We fit our model to each TCGA GBM RNAsequencing dataset individually (Fig. 2D ). We found that samples of both the mesenchymal and classical Verhaak subtypes are enriched for mGSCs and depleted of pGSCs. While classical samples are distinguished by higher infiltration of astrocytes, mesenchymal samples contain high levels of infiltrating immune cells. Proneural samples are characterized by the highest levels of pGSCs, oligodendrocytes and neurons. In summary, the full spectrum of heterogeneity observed in TCGA GBM data can be explained by varying proportions of GSCs, their differentiated progeny and infiltrating stromal/immune content.
GSCs explain their specimen's genetic heterogeneity but only mGSC content is prognostic
We applied our pipeline for identifying single-nucleotide variants (SNVs) and megabase-scale copy-number variants (CNVs) to our exome-seq data (3, 6) . We restricted ourselves to mutations that occurred at a minimum of 10% variant allele frequency and identified cells in our scRNA-seq which expressed these mutations. For all patients, we found that all expressed, validated mutations are present in the GSCs (Fig. 2E and S3 ). We found that mGSCs possess a greater representation of mutations than pGSCs in all specimens. This result holds even if we increase the stringency in GSC assignment by thresholding the stemness score (Fig. 2F ). Cox-regression analysis identifies the mGSC signature as correlating with significantly inferior survival in TCGA data. However, pGSC content is not prognostic (Fig.  2G ).
GSC niche localization and microenvironment interactions elucidated using reference atlases and quantitative IHC
We compared our mGSC, pGSC and cell-cycle signatures to RNA sequencing from the GAP (Fig. 3A-B) . The GAP has annotated, microdissected and RNA sequenced GBM anatomical structures from human specimens. We found that mGSCs are enriched in hypoxic regions. PGSCs are enriched in the tumor's leading edge and in regions of diffuse infiltration of tumor-adjacent white matter.
To infer GSC interactions with the microenvironment, we compared our scRNA-seq to a database of known receptor-agonist interactions. We annotated cognate pairs that were co-expressed by neoplastic and nonneoplastic cells from the same sample (table S5) . We found that mGSCs compared to pGSCs express a greater diversity of surface receptors responsive to ligands expressed by stromal and immune cells (Fig. 3C) .
To visualize and quantify the associations between GSCs, cell cycle and hypoxia, we performed IHC for CD44 (mGSCs), DLL3 (pGSCs), CA9 (hypoxia) and Ki67 (cell cycle) on GBM microarrays ( Fig. 4A ; table S6), as well as positive and negative control tissues (Fig. S4 ). We did not find any cycling CD44+ cells in our samples, while approximately 5% of DLL3+ cells expressed Ki67. On the other hand, CD44+ cells colocalized with CA9 at 2-fold greater frequency than DLL3+ cells (Fig. 4B ). This dovetails with our findings in scRNA-seq, TCGA and GAP data, which show that pGSCs are more proliferative while mGSCs are enriched in hypoxic regions.
Discussion
It is known that an individual tumor may contain multiple GSC clones (e.g. 13). We applied exome-seq and scRNA-seq to human tissues and found that all GBMs contain hierarchies of mesenchymal and proneural GSCs and their more differentiated progeny. However, the functional differences between GSC populations have not been fully determined.
Murine GBMs can be separated into two cell populations that have different capacities for tumorigenicity and self-renewal (14) . The their lineage relationships and functional differences is needed to develop combination therapies that address intratumor heterogeneity.
Materials and Methods
Tumor tissue acquisition and processing
We acquired fresh tumor tissue and peripheral blood from patients undergoing surgical resection for GBM. De-identified samples were provided by the Neurosurgery Tissue Bank at the University of California San Francisco (UCSF). Sample use was approved by the Institutional Review Board at UCSF. The experiments performed here conform to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. All patients provided informed written consent. Tissues were minced in collection media (Leibovitz's L-15 medium, 4 mg/mL glucose, 100 u/mL Penicillin, 100 ug/mL Streptomycin) with a scalpel. Samples dissociation was carried out in a mixture of papain (Worthington Biochem. Corp) and 2000 units/mL of DNase I freshly diluted in EBSS and incubated at 37 °C for 30 min. After centrifugation (5 min at 300 g), the suspension was resuspended in PBS. Subsequently, suspensions were triturated by pipetting up and down ten times and then passed through a 70-μm strainer cap (BD Falcon). Last, centrifugation was performed for 5 min at 300 g. After resuspension in PBS, pellets were passed through a 40-μm strainer cap (BD Falcon), followed by centrifugation for 5 min at 300 g. The dissociated, single cells were then resuspended in GNS (Neurocult NS-A (Stem Cell Tech.), 2 mM L-Glutamine, 100 U/mL Penicillin, 100 ug/mL Streptomycin, N2/B27 supplement (Invitrogen), sodium pyruvate).
Fluidigm C1-based scRNA-seq
Fluidigm C1 Single-Cell Integrated Fluidic Circuit (IFC) and SMARTer Ultra Low RNA Kit were used for single-cell capture and complementary DNA (cDNA) generation. cDNA quantification was performed using Agilent High Sensitivity DNA Kits and diluted to 0.15-0.30 ng/μL. The Nextera XT DNA Library Prep Kit (Illumina) was used for dual indexing and amplification with the Fluidigm C1 protocol. Ninety-six scRNA-seq libraries were generated from each tumor/Cd11b + sample and subsequently pooled for 96-plex sequencing. cDNA was purification and size selection were carried out twice using 0.9X volume of Agencourt AMPure XP beads (Beckman Coulter). The resulting cDNA libraries were quantified using High Sensitivity DNA Kits (Agilent).
10X genomics-based scRNA-seq
Tissue was dissociated by incubation in papain with 10% DNAse for 30 min. A single-cell suspension was obtained by manual trituration using a glass pipette. The cells were filtered via an ovomucoid gradient to remove debris, pelleted, and resuspended in Neural Basal Media with serum at a concentration of 1700 cells/uL. In total, 10.2 uL of cells were loaded into each well of a 10X Chromium Single Cell capture chip and a total of two lanes were captured. Single-cell capture, reverse transcription, cell lysis, and library preparation were performed per manufacturer's protocol. Sequencing for both platforms was performed on a HiSeq 2500 (Illumina, 100-bp paired-end protocol).
